Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its holdings in Becton Dickinson and Co (NYSE:BDX) by 4.8% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 76,555 shares of the medical instruments supplier’s stock after selling 3,900 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Becton Dickinson and were worth $17,590,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in BDX. IndexIQ Advisors LLC acquired a new stake in Becton Dickinson and during the fourth quarter worth approximately $25,000. Verus Capital Partners LLC purchased a new position in shares of Becton Dickinson and in the 4th quarter valued at $27,000. Pinnacle Financial Partners Inc. purchased a new position in shares of Becton Dickinson and in the 4th quarter valued at $31,000. Cedar Mountain Advisors LLC acquired a new stake in Becton Dickinson and during the 4th quarter worth $42,000. Finally, Harwood Advisory Group LLC purchased a new stake in Becton Dickinson and in the first quarter valued at $50,000. Institutional investors own 86.79% of the company’s stock.

A number of analysts have recently commented on the company. Citigroup lifted their target price on Becton Dickinson and from $234.00 to $260.00 and gave the stock a “neutral” rating in a research report on Friday, May 8th. SVB Leerink restated a “market perform” rating and set a $262.00 price target (up previously from $245.00) on shares of Becton Dickinson and in a research note on Friday, May 8th. Stifel Nicolaus lifted their price target on Becton Dickinson and from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. TheStreet downgraded Becton Dickinson and from a “b” rating to a “c+” rating in a report on Monday, March 9th. Finally, Piper Sandler lifted their target price on shares of Becton Dickinson and from $286.00 to $296.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Becton Dickinson and presently has an average rating of “Hold” and a consensus target price of $275.79.

NYSE:BDX traded up $0.31 during midday trading on Friday, reaching $239.25. The stock had a trading volume of 11,783,270 shares, compared to its average volume of 1,932,654. The company has a quick ratio of 0.66, a current ratio of 0.98 and a debt-to-equity ratio of 0.80. The stock has a market cap of $64.79 billion, a P/E ratio of 72.06, a P/E/G ratio of 2.57 and a beta of 0.95. The firm has a fifty day simple moving average of $253.35 and a two-hundred day simple moving average of $255.35. Becton Dickinson and Co has a 12-month low of $197.75 and a 12-month high of $286.72.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.32 by $0.23. The business had revenue of $4.25 billion for the quarter, compared to the consensus estimate of $4.10 billion. Becton Dickinson and had a net margin of 6.10% and a return on equity of 15.75%. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.59 earnings per share. On average, sell-side analysts anticipate that Becton Dickinson and Co will post 10.5 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 1.32%. The ex-dividend date of this dividend is Monday, June 8th. Becton Dickinson and’s payout ratio is 27.05%.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: Candlestick

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.